However, a growing body of evidence indicates that BRCA1 and BRCA2 TN as well as luminal cancers are more chemosensitive and achieve higher pathologic complete response (pCR) rates compared with breast cancer without the BRCA1 or BRCA2 pathogenic variant [69,70]. This evidence concerns the gene BRCA1 and breast cancer.